U.S. Markets closed

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3000-0.0200 (-1.52%)
At close: 4:00PM EDT
1.3000 0.00 (0.00%)
After hours: 07:54PM EDT

Alterity Therapeutics Limited

460 Bourke Street
Level 3
Melbourne, VIC 3000
61 3 9349 4906

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoffrey Paul Kempler B.Sc., B.ScCo-Founder & Non-Exec. Chairman336.05kN/A1955
Dr. David A. StamlerCEO, Chief Medical Officer & Sr. VP of Clinical Devel.471.27kN/A1961
Ms. Kathryn J. E. AndrewsChief Financial Officer194.29kN/A1967
Dr. Rudolph Emile TanziChief Scientific Advisor and Member of R&D Advisory BoardN/AN/AN/A
Dr. Steven D. TargumChief Medical AdvisorN/AN/AN/A
Dr. Robert ChernyHead of ResearchN/AN/AN/A
Mr. Phillip Allen HainsCompany Sec.N/AN/A1959
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

Corporate Governance

Alterity Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.